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Summary
 
The related adhesion focal tyrosine kinase (RAFTK), a recently discovered member of the fo-
cal adhesion kinase family, has previously been reported to participate in signal transduction in
neuronal cells, megakaryocytes, and B lymphocytes. We have found that RAFTK is constitu-
tively expressed in human T cells and is rapidly phosphorylated upon the activation of the T cell
receptor (TCR). This activation also results in an increase in the autophosphorylation and ki-
nase activity of RAFTK. After its stimulation, there was an increase in the association of the 
 
src
 
cytoplasmic tyrosine kinase 
 
Fyn
 
 and the adapter protein Grb2. This association was mediated
through the SH2 domains of 
 
Fyn
 
 and Grb2. RAFTK also co-immunoprecipitates with the
SH2 domain of 
 
Lck
 
 and with the cytoskeletal protein paxillin through its COOH-terminal
proline-rich domain. The tyrosine phosphorylation of RAFTK after T cell receptor-mediated
stimulation was reduced by the pretreatment of cells with cytochalasin D, suggesting the role of
the cytoskeleton in this process. These observations indicate that RAFTK participates in T cell
receptor signaling and may act to link signals from the cell surface to the cytoskeleton and
thereby affect the host immune response.
 
T
 
ransduction of signals from cell surface receptors in-
volves the activation of numerous molecules having
catalytic activity related to phosphorylation. In the case of
signaling after the ligation of the TCR/CD3, there is the
associated release of calcium, activation of intracytoplasmic
protein tyrosine kinases including 
 
Fyn
 
 and 
 
Lck
 
, modulation
in phosphatidylinositol metabolism with phosphorylation
of PLC-
 
g
 
, and changes in the Ras pathway (1–13). Associ-
ated with these activation events, there are changes within the
cytoplasm that include alterations in the cytoskeleton (14–17).
Although considerable knowledge has been generated on
such pathways in the T cell response to antigen, there is still
much to be learned, particularly regarding the interactions of
kinase signaling molecules with the cytoskeletal proteins. One
recent study revealed that activation via TCR/CD3 led to im-
portant associations and changes in the actin cytoskeleton (17).
We and others have recently identified a novel signaling
molecule known as related adhesion focal tyrosine kinase
(RAFTK)
 
1
 
, Pyk2, or CAK-
 
b
 
 (18–20). This molecule is
most closely related to the focal adhesion kinase (FAK).
FAK has been shown to associate with several signaling
molecules and cytoskeletal structures that form in the so-
called focal adhesions upon cell attachment to extracellular
substrates (21–24). RAFTK has considerable deduced amino
acid and structural similarity with FAK, including consen-
sus motifs in the central catalytic domain, the absence of a
transmembrane region, myristylation sites, and SH2 and
SH3 domains. Also, similar to FAK, RAFTK has a proline-
rich region in the COOH-terminal domain (18–20).
We have observed that RAFTK is phosphorylated in re-
sponse to the activation of certain integrins in B lympho-
cytes (25) and megakaryocytes (26). The induced phosphor-
ylation of RAFTK via calcium-mediated ion channel
pathways and after stress activation has been shown in PC-
12 pheochromocytoma cells (19, 27, 28).
We report the finding that RAFTK is expressed in hu-
man T lymphocytes and participates in signaling events
triggered by the ligation of the TCR/CD3 complex. We
have characterized several of the interacting molecules that
associate with RAFTK in human T cells, including the cy-
toskeletal protein paxillin. These studies provide new in-
formation regarding the regulation of pathways of T cell
 
1
 
Abbreviations used in this paper:
 
 FAK, focal adhesion kinase; GST, Glu-
tathione S transferase; RAFTK, related adhesion focal tyrosine kinase;
RIPA, radioimmunoprecipitation assay; RT, room temperature.
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receptor signaling and the associated cytoskeletal changes
that may mediate the cellular immune response.
 
Materials and Methods
 
Cells and Cell Cultures.
 
The permanent human T cell lines
Jurkat and H9 were obtained from the American Type Culture
Collection (Rockville, MD) and shown to be mycoplasma-free
before their expansion in culture. The cells were carried in DME
with 10% FCS, 2 mM glutamine, 50 
 
m
 
g/ml penicillin, and 50 
 
m
 
g/
ml streptomycin. Primary human PBLs were obtained from nor-
mal volunteers after obtaining their informed consent and then iso-
lated by Ficoll Hypaque density centrifugation as previously de-
scribed (29). The anti-CD3–producing hybridoma (OKT-3) was
obtained from the American Type Culture Collection and grown
in IMDM with 20% FCS. For antibody production, cells were
grown in serum- and protein-free hybridoma medium (Sigma
Chemical Co., St. Louis, MO) containing Nutridoma-HU 1%
(Boehringer Mannheim, Indianapolis, IN).
 
Reagents and Materials.
 
The lectin PHA was obtained from
Pharmacia Biotech (Piscataway, NJ) and the nitrocellulose mem-
brane from BioRad Laboratories (Hercules, CA). The anti-CD3
antibody X35 was obtained from Immunotech (Westbrook, ME),
and OKT-3 was purified from OKT-3–producing hybridoma su-
pernatants on protein A–Sepharose columns. Antibodies to 
 
Fyn
 
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA)
and Transduction Laboratories (Lexington, KY). Anti–paxillin anti-
body was obtained from ICN Biomedicals, Inc. (Costa Mesa, CA).
Specific polyclonal antibodies to RAFTK were generated by im-
munizing New Zealand white rabbits with a bacterially expressed
fusion protein consisting of GST and the COOH terminus (amino
acids 681–1,009) of the human RAFTK cDNA subcloned into
the pGEX-2T expression vector as described (26). The sera were
titered against the GST-RAFTK COOH-terminal fusion protein
by ELISA, and the serum (R-4250) that revealed the highest titer
was used in the subsequent experiments. This antiserum was shown
to be specific and not cross-reactive with FAK in earlier experi-
ments (26). Electrophoresis reagents were obtained from BioRad
Laboratories. The protease inhibitors leupeptin, aprotinin, and al-
pha 1 antitrypsin and all other reagents were obtained from Sigma
Chemical Co.
 
Stimulation of Cells.
 
Cells were washed twice with HBSS,
(GIBCO BRL, Gaithersburg, MD) and resuspended at 5 
 
3
 
 10
 
6
 
cells/ml in DME. Cells were stimulated with either PHA (10 
 
m
 
g/
ml), 
 
a
 
-CD3 antibodies 
 
3
 
35 (10 
 
m
 
g/ml), or OKT-3 (10 
 
m
 
g/ml)
at 37
 
8
 
C for various time periods. In some experiments, cells were
pretreated with EGTA (5 mM) for 5 min at 4
 
8
 
C or cytochalasin D
(2 
 
m
 
M) for 60 min at 37
 
8
 
C before stimulation. After stimulation,
2 
 
3
 
 10
 
7
 
 cells were microfuged for 10 s and lysed in 1 ml of mod-
ified radioimmunoprecipitation assay (RIPA) buffer (50 mM
Tris-HCl, pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150
mM NaCl, 1 mM PMSF, 10 
 
m
 
g/ml of aprotinin, leupeptin, and
pepstatin, 10 mM sodium vanadate, 10 mM sodium fluoride, and
10 mM sodium pyrophosphate). Total cell lysates were clarified
by centrifugation at 10,000 
 
g
 
 for 10 min. Protein concentrations
were determined by protein assay (BioRad Laboratories).
 
Immunoprecipitation and Western Blot Analysis.
 
For immunopre-
cipitation studies, identical amounts of protein from each sample
were clarified by incubation with protein A–Sepharose CL-4B
(Pharmacia Biotech) for 1 h at 4
 
8
 
C. After the removal of protein
A–Sepharose by brief centrifugation, the solution was incubated
with different primary antibodies as detailed below for each ex-
periment for 4 h or overnight at 4
 
8
 
C. Immunoprecipitations of
the antibody–antigen complexes were performed by incubation
for 2 h at 4
 
8
 
C with 75 
 
m
 
l of protein A–Sepharose (10% suspen-
sion). Nonspecific bound proteins were removed by washing the
Sepharose beads three times with modified RIPA buffer and one
time with PBS. Bound proteins were solubilized in 40 
 
m
 
l of 2
 
3
 
Laemmli buffer and further analyzed by immunoblotting. Sam-
ples were separated on 7.5% SDS-PAGE and then transferred to
nitrocellulose membranes. The membranes were blocked with 5%
nonfat milk protein and probed with primary antibody for 3 h at
room temperature (RT) or 4
 
8
 
C overnight. Immunoreactive
bands were visualized using HRP-conjugated secondary antibody
and the enhanced chemiluminescent system (Amersham Corp.,
Arlington Heights, IL). Monoclonal antibody (4G10, IgG2a) was
used for Western blot analysis of phosphotyrosine protein.
 
Glutathione S Transferase Fusion Protein Binding Studies.
 
The RAFTK
COOH-terminal domain (amino acids 681 through 1,009) Glu-
tathione S transferase (GST) fusion protein was amplified by the
PCR technique and cloned into the pGEX-2T expression vector
(Pharmacia Biotech) as previously described (26). The GST–
fusion protein was produced by 1 mM isopropyl 
 
b
 
-thiogalacto-
pyranoside induction and purified on a Glutathione–Sepharose
column by affinity chromatography according to manufacturer’s
recommendations (Pharmacia Biotech). GST–fusion protein Grb2-
SH3 NH
 
2
 
-terminal domain, Grb2-SH3 COOH-terminal domain,
Grb2-SH2 domain, and 
 
Fyn
 
-SH2 and -SH3 domains were pur-
chased from Santa Cruz Biotechnology. For the binding experi-
ments, 1 mg of cell lysate was mixed with 5 
 
m
 
g of GST–fusion pro-
tein and incubated for 1 h at 4
 
8
 
C on a rotatory shaker. GST
protein (Santa Cruz Biotechnology) was used as control. 50 
 
m
 
l of
Glutathione–Sepharose 4B beads (Pharmacia Biotech) were added
to preabsorb the complex. After incubation for 3 h at 4
 
8
 
C on a
rotatory shaker, the beads were centrifuged and washed three times
with modified RIPA buffer. The bound proteins were eluted by
boiling in Laemmli sample buffer and subjected to 7.5% SDS-
PAGE and Western blot analysis.
 
Kinase Assays.
 
The immunoprecipitated complexes obtained
by immunoprecipitating cell lysates with RAFTK antiserum were
washed twice with RIPA buffer and once in kinase buffer (20 mM
Hepes, pH 7.4, 50 mM NaCl, 5 mM MgCl
 
2
 
, 5 mM MnCl
 
2
 
, 100
mM Na
 
3
 
VO
 
4
 
, and 5 
 
m
 
M ATP). For in vitro kinase assays, the im-
mune complex was incubated in kinase buffer containing 25 
 
m
 
g
of poly (Glu/Tyr, 4:1; 20–50 kD; Sigma Chemical Co.) and 5 
 
m
 
Ci
[
 
32
 
P]ATP at RT for 30 min.
 
Autophosphorylation Assay.
 
This assay was carried out by incu-
bating the immune complex in a kinase buffer containing 5 
 
m
 
Ci
[
 
32
 
P]ATP at RT for 30 min. The reaction was stopped by adding
4
 
3
 
 SDS sample buffer and by boiling the sample for 5 min. Pro-
teins were then separated on SDS-PAGE and detected by autora-
diography.
 
Results
 
RAFTK Is Expressed in Human T Lymphocytes and Is
Phosphorylated upon T Cell Activation.
 
To further charac-
terize the signaling pathways in human T cells involved in
the immune response, we used as models two permanent
T cell lines, Jurkat and H9, as well as primary human PBLs.
Analysis by immunoblotting (data not shown) or immuno-
precipitation revealed abundant RAFTK protein in these T
cells (Fig. 1).
The stimulation of human T cell lines with T cell recep-
tor ligation induces the tyrosine phosphorylation of a phos- 
1057
 
Ganju et al.
 
phoprotein around 115 kD (5, 7). We therefore investi-
gated whether various stimuli associated with such T cell
activation modulated the phosphorylation of RAFTK, which
has a deduced molecular weight of 
 
z
 
120 kD. As seen in
Fig. 1, 
 
A
 
 and 
 
B
 
, an increase in the tyrosine phosphorylation
of RAFTK could be specifically observed in the T cell lines
Jurkat or H9 after T cell receptor ligation or treatment with
the lectin PHA. The membrane was then stripped and re-
probed with anti–RAFTK antibody to confirm that equiv-
alent amounts of RAFTK were loaded in each lane (Fig. 1,
 
A
 
 and 
 
B
 
, 
 
bottom
 
). Stimulation of primary PBLs with anti–T
cell receptor antibody also induced an increase in the ty-
rosine phosphorylation of RAFTK (Fig. 1 
 
C
 
).
To determine the time course of tyrosine phosphoryla-
tion of RAFTK, Jurkat cells were stimulated with anti–T
cell receptor antibody 
 
3
 
35, OKT-3, or with the lectin
PHA. Ligation of the TCR/CD3 by monoclonal antibody
 
3
 
35 or OKT-3 reached a maximum by 2.5–5 min, and
declined thereafter (Fig. 2, 
 
A
 
 and 
 
B
 
). PHA stimulation re-
sulted in an increased tyrosine phosphorylation by 5 min
that declined slightly thereafter with substantial phosphory-
lation still detectable at 20 min (Fig. 2 
 
C
 
). Anti-RAFTK
immunoblotting of the anti-RAFTK immunoprecipitates
showed that the 
 
z
 
115-kD phosphotyrosine polypeptide
corresponds to the RAFTK protein (Fig. 2, 
 
A–C
 
, 
 
bottom
 
).
Depending on the resolution of the gels, RAFTK was seen
to migrate either as a single band or as a doublet (Figs. 1
and 2).
 
T Cell Receptor Stimulation Results in Increased RAFTK
Autophosphorylation and Kinase Activity.
 
The autophosphory-
lation  and kinase activities of protein tyrosine kinases can be
activated upon their tyrosine phosphorylation, which is es-
sential for their role in signal transduction. We therefore
performed an autophosphorylation assay and an in vitro ki-
nase assay in which poly (Glu/Tyr, 4:1) was used as an exo-
genous substrate to determine the intrinsic tyrosine kinase
activity of RAFTK. As shown, T cell receptor stimulation
resulted in an increase in the autophosphorylating (Fig. 3 
 
A
 
)
as well as the kinase activity of RAFTK (Fig. 3 
 
B
 
). In the au-
tophosphorylation assays, maximal activity was observed at
 
z
 
2.5–5 min. However, for the in vitro kinase assays, max-
imal activity was observed at 
 
z
 
5–10 min. The different ki-
netics observed in autophosphorylation versus in vitro ki-
nase assay could be attributed to the differences in the
assays used. The in vitro kinase activity observed in the
RAFTK immune complexes using exogenous substrate
Figure 1. Tyrosine phosphorylation of RAFTK by T cell receptor cross-linking in Jurkat and H9 human T cell lines or primary human PBLs. Cells were
lysed in RIPA buffer. Lysates obtained from 2 3 107 unstimulated (2), a-CD3-stimulated or PHA-stimulated Jurkat cells (A), H9 cells (B), or primary
human PBLs (C) were immunoprecipitated with RAFTK polyclonal antibody. Immunoprecipitates were size-fractionated on 7.5% SDS-PAGE gels,
transferred to nitrocellulose membranes, and then subjected to serial immunoblotting with anti–phosphotyrosine antibody (4G10; top) and anti-RAFTK
antibody (bottom). Normal rabbit serum (NRS) was used as a negative control. TCL, total cell lysates.
Figure 2. Time course of tyrosine phosphorylation of RAFTK upon T cell activation. Jurkat cells (5 3 106/ml) were incubated at 378C for different
time periods with either (A) anti-CD3 antibodies 335 (10 mg/ml), (B) OKT-3 (10 mg/ml), or (C) PHA (10 mg/ml). Stimulated or unstimulated cells
were lysed in RIPA buffer, immunoprecipitated with anti-RAFTK antibody, resolved on SDS-PAGE gels, and subjected to serial immunoblotting with
anti–phosphotyrosine antibody (top) and RAFTK antibody (bottom).1058 Role of RAFTK in T Cell Receptor Signaling
could be the result of RAFTK and other co-associated ki-
nases such as Fyn.
RAFTK Associates with the Signaling Molecules Fyn and
Grb2. To further characterize the role that RAFTK
might play in T cell signaling after its activation via TCR/
CD3 ligation, we performed immunoprecipitation studies
followed by immunoblotting. We observed a specific asso-
ciation of RAFTK with Fyn, a Src family kinase that is
known to be capable of associating with TCR (12, 30–32).
A small fraction of Fyn was readily detected as associating
with RAFTK before the TCR/CD3 activation of Jurkat
cells, and this association increased after their stimulation
(Fig. 4 A).
Using GST–fusion proteins corresponding to the SH3
and SH2 domains of Fyn, we observed an association only
with the GST-SH2-Fyn protein by immunoprecipitation
of the fusion protein followed by immunoblotting with
anti-RAFTK antibody (Fig. 4 B). The SH2 domain of Lck,
another Src family member, has recently been shown to
play an important role in the initiation of signaling events
after TCR stimulation (33). We also examined the associa-
tion of the GST-SH2 domain of Lck with RAFTK. As
shown (Fig. 4 B), RAFTK also co-immunoprecipitates
with the GST-SH2 domain of Lck.
We then examined the ability of RAFTK to form in
vitro complexes with another SH2 and SH3 domain–con-
taining protein, Grb2, which has been shown to interact
with RAFTK in other cells (19, 26). As shown in Fig. 5 A,
RAFTK immunoprecipitates from activated T cell lysates
associated with Grb2. To further characterize this interac-
tion, GST–fusion proteins of the RAFTK–COOH-termi-
nal domain, of Grb2-SH2, or of Grb2-SH3 domains were
added to the lysates of the stimulated Jurkat cells. The com-
plexes were immunoprecipitated with Glutathione-conju-
gated beads and the bound proteins were detected by anti-
Grb2 (Fig. 5 B) or anti-RAFTK immunoblotting (Fig. 5 C).
The GST-RAFTK–COOH-terminal domain associated
with Grb2 (Fig. 5 B), whereas Sepharose beads containing
the GST-Grb2-SH2 domain bound RAFTK from the acti-
vated T cell lysates (Fig. 5 C). Beads containing only GST,
GST–NH2-terminal Grb2-SH3, or GST–COOH-terminal
Grb2-SH3 failed to bind RAFTK, indicating the specificity
of these interactions (Fig. 5 C). These data clearly indicate
that the stable interaction between RAFTK and the SH2
domain of Fyn or the SH2 domain of Grb2 can be mim-
icked in vitro and provide additional evidence that the SH2
domain of these signaling molecules appears to be the prin-
cipal determinant of RAFTK binding in vivo.
RAFTK Associates with the Cytoskeletal Protein Paxillin.
After our observation that RAFTK may be co-immuno-
precipitated with molecules previously characterized as com-
ponents of the TCR signaling pathways, we wished to de-
termine whether certain cytoskeletal molecules in T cells
may also associate with this novel kinase. Using specific an-
Figure 3. RAFTK activation after T cell receptor stimulation. Unstim-
ulated or stimulated Jurkat cell lysates were immunoprecipitated with
RAFTK antibody. The immune complexes were either subjected to au-
tophosphorylating activity (A) or in vitro kinase assays, using poly (Glu/
Tyr, 4:1) substrate (B). The 32P-incorporated proteins were resolved on
7.5% SDS-PAGE followed by autoradiography.
Figure 4. Association of RAFTK with Fyn and the SH2 domain of
Lck. (A) Jurkat cells unstimulated or stimulated with anti-CD3 antibody
OKT-3 (10 mg/ml) for different time periods were lysed in RIPA buffer
and immunoprecipitated with RAFTK antibody. Immunoprecipitated
complexes were resolved on 7.5% SDS-PAGE and immunoblotted with
either anti-Fyn antibody (A, top) or RAFTK antibody (A, bottom). (B)
Stimulated Jurkat cell lysates were incubated with GST-Fyn SH2 or SH3,
or GST-Lck SH2 fusion proteins which were immunoprecipitated with
Glutathione beads. The immunoprecipitates were run on 7.5% gels, trans-
ferred onto nitrocellulose membranes, and blotted with RAFTK anti-
body. GST protein only was used as a control.1059 Ganju et al.
tibodies to RAFTK or paxillin, we found a constitutive as-
sociation of these two molecules (Fig. 6 A). Using the
GST–COOH-terminal RAFTK protein, we observed a
modestly increased association with paxillin after TCR/
CD3 stimulation with anti-CD3 antibody (Fig. 6 B).
RAFTK Phosphorylation Is Inhibited by EGTA and Cytocha-
lasin D. To examine the effect of calcium influx on TCR-
induced activation of RAFTK, we treated Jurkat cells with
anti-CD3 antibody in the presence or absence of the cal-
cium chelator EGTA. The TCR-induced phosphorylation
of RAFTK was partially reduced in the presence of EGTA
(Fig. 7 A). This result suggests that the phosphorylation of
RAFTK can be mediated in part by the increase in intra-
cellular calcium concentration that is mediated by these
stimuli.
To further investigate the role of the cytoskeleton in the
tyrosine phosphorylation of RAFTK, Jurkat T cells were
preincubated for 60 min at 378C with media alone (2 CD)
or with media plus cytochalasin D (1 CD) before TCR
stimulation. Cytochalasin D is known to disrupt the cy-
toskeletal structure in T lymphocytes and other cells (14,
17, 34). The phosphorylation of RAFTK was reduced after
the cytochalasin D treatment of cells (Fig. 7 B). No change
in the levels of RAFTK proteins was observed under these
conditions (Fig. 7 B). These results suggest that an intact
cytoskeleton is important in RAFTK phosphorylation after
TCR stimulation.
Discussion
Our studies indicate that RAFTK, a novel signaling
molecule that appears to be a member of the FAK family, is
present in human T lymphocytes and participates in signal-
ing pathways after T cell activation. After the ligation of
the TCR/CD3, there was a robust phosphorylation of
RAFTK in both the model permanent T cell lines Jurkat
and H9, as well as in primary human PBLs. Furthermore,
Figure 5. Association of RAFTK and the adapter protein Grb2 after T
cell activation. Cell lysates from Jurkat cells unstimulated or stimulated
with anti-CD3 antibody for different time periods were immunoprecipi-
tated with RAFTK antibody. (A) The immune complexes were resolved
on 12.5% SDS-PAGE and immunoblotted with anti-Grb2 antibody. (B)
Cell lysates were immunoprecipitated with the COOH terminus of
RAFTK GST–fusion protein, run on 12.5% SDS-PAGE and blotted with
Grb2 antibody. (C) The cell lysates were immunoprecipitated with the
SH3 and SH2 domains of Grb2 and blotted with RAFTK antibody.
Figure 6. Association of RAFTK with the cytoskeletal protein paxillin.
(A) Unstimulated or stimulated Jurkat cell lysates were immunoprecipitated
with RAFTK antibody, separated on 7.5% gels, and immunoblotted with
paxillin antibody. (B) In other experiments, the GST RAFTK COOH-ter-
minal domain protein or GST protein alone as a control was added to un-
stimulated or stimulated Jurkat cell lysates and immunoprecipitated with
Glutathione–Sepharose beads followed by immunoblotting with anti–
paxillin antibody.1060 Role of RAFTK in T Cell Receptor Signaling
RAFTK was also activated, which was apparent both in the
enhanced autophosphorylation of RAFTK as well as the
increase in its in vitro kinase activity as determined using a
poly (Glu/Tyr, 1:4) substrate. Parallel studies using other
T cell activators, specifically the lectin PHA, revealed a sim-
ilar phosphorylation of RAFTK in a time- and concentra-
tion-dependent manner. Furthermore, it appears that calcium
influx may be required for the TCR-mediated tyrosine phos-
phorylation of RAFTK, as depletion of extracellular calcium
by EGTA partially blocked the RAFTK phosphorylation
induced by these stimuli. Pyk2/RAFTK phosphorylation
has also been shown to be associated with changes in cal-
cium in other cell types (19, 27, 28).
It is noteworthy that after phosphorylation, RAFTK was
found to be associated with several well-characterized
components of the TCR/CD3 signaling pathways, includ-
ing Fyn and Grb2. Fyn is a Src family tyrosine kinase known
to be capable of associating with the TCR/CD3 complex,
and is also believed to play an important role in initiating
the changes in phosphorylation that lead to further down-
stream signaling. This role has been most clearly demon-
strated in studies showing the impaired development of CD41
CD81 thymocytes from double mutant mice rendered null
for Fyn and FAK through homologous recombination (35).
In addition, thymocytes from transgenic mice overexpress-
ing Fyn were hyperstimulatable, and overexpression of a
catalytically inactive form of Fyn substantially inhibited
TCR-mediated activation in otherwise normal thymocytes
(36). Grb2 is a well-characterized adapter molecule that is
capable of associating with a number of kinases and sub-
strates and may also act to facilitate signaling through the
enhancement of the physical association of such partners in
enzymatic reactions (37–39). Grb2 and Shc have also been
shown to play an important role in T cell signaling (5, 40–
42). Recently, in PC12 pheochromocytoma cells, Pyk2/
RAFTK has been shown to associate with activated src ki-
nase. This interaction occurred through the SH2 domain
of src, which bound to the COOH terminus of Pyk2/
RAFTK (28). The SH2 domain of Fyn has also been
shown to associate with RAFTK in other cell types (26).
Also in PC12 cells, Grb2 has been reported to be associated
with Pyk2/RAFTK (19). Thus, there appears to be similar-
ities in the associations of activated RAFTK with certain
signaling molecules in different cell types. RAFTK also as-
sociates with the SH2 domain of Lck, which has been
shown to play an important role in TCR-induced signal
transduction (33).
Our observations on RAFTK suggest that this novel sig-
naling molecule could play a variety of roles in the trans-
duction of T cell signals. Although further work is required
to elucidate such functions of RAFTK, the association of
RAFTK with the cytoskeletal protein paxillin provides a
direction for these future efforts. The confluence of signal-
ing molecules and cytoskeletal components may provide a
platform for the regulated interactions of kinases and sub-
strates and may lead to important changes in cell morphology
that enable other aspects of the immune response such as
adhesion or migration. Work in adherent mesenchymal cells
indicates that the formation of the so-called focal adhesions
may facilitate the creation of these platforms and mediate cell
attachment and transduction of signals (23, 24, 43). Rela-
tively little is known about similar mechanisms in hemato-
poietic cells like T lymphocytes. Recently, another member
of the FAK family, termed FAK B, was identified. Initial
studies indicated that FAK B may associate with ZAP-70,
an intracytoplasmic protein tyrosine kinase also capable of
associating with TCR (44). Amino acid sequence analysis
demonstrates that RAFTK is not FAK B; however, future
studies of the possible association of RAFTK with FAK B
or with stimulatory molecules like ZAP-70 will be of value
in elucidating these signaling mechanisms.
There is relatively limited information available on the
convergence of protein tyrosine kinases and cytoskeletal ele-
ments in T lymphocytes. Several T cell surface structures,
including CD11a/CD18 and CD44, associate with the cy-
Figure 7. TCR-stimulated tyrosine phosphorylation of RAFTK partly
requires calcium and an intact cytoskeleton. Jurkat cells were preincu-
bated with medium plus EGTA (5 mM) or medium alone for 5 min at
48C (A). Similarly, cells were also preincubated with cytochalasin D (2 mM;
1CD) or medium alone (2CD) for 60 min at 378C (B). Unstimulated
cells (2) or cells stimulated for different time periods at 378C with anti-
CD3 monoclonal antibody were lysed and immunoprecipitated with
RAFTK antibody. The immunoprecipitated complexes were resolved on
7.5% SDS-PAGE and immunoblotted with anti-phosphotyrosine anti-
body (top), and then stripped and reblotted with antiserum to RAFTK
(bottom).1061 Ganju et al.
toskeleton upon receptor cross-linking. Recently, the in-
teraction of the z chain of TCR with the actin cytoskele-
ton upon T cell activation was demonstrated (17). Our
results revealed that RAFTK co-associates with paxillin, a
major component of the cytoskeleton. Like FAK, the pro-
line-rich COOH terminus of RAFTK binds to paxillin
(24). Furthermore, the pretreatment of cells with cytocha-
lasin D results in the reduced tyrosine phosphorylation of
RAFTK upon T cell receptor activation. This result sug-
gests that RAFTK phosphorylation may require the forma-
tion of a cytoskeletal complex, which provides a foundation
for the interactions and compartmentalization of kinases
and substrates. Future studies will further define whether
other cytoskeletal components are associated with RAFTK
upon T cell activation.
It has been suggested that in addition to FAK B, FAK
may also participate in regulatory events after T lymphocyte
activation (45). These earlier data, in conjunction with the
results from our study, strongly suggest that molecules like
FAK and RAFTK are important in coordinating a reper-
toire of kinases and adapter molecules in T cells, which then
are capable of transmitting regulated signals downstream to
the transcriptional activators that modulate gene expression.
In this regard, in the PC12 neuronal cell model, Pyk2/
RAFTK activation coupled stress signals to the c-Jun–NH2
terminal kinase pathway (27). This pathway is known to
activate AP-1 and has been previously reported to partici-
pate in T lymphocyte signaling after costimulation (46, 47).
Our future focus will be to assess whether inherited or ac-
quired abnormalities in T cell function involve the activa-
tion and subsequent associative functions of RAFTK as it
colocalizes signaling molecules with the cytoskeleton, and
how this may be linked to transcriptional activation.
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